Asset Details
Do you wish to reserve the book?
Efficacy of atorvastatin on renal function in patients with contrast-induced nephropathy after percutaneous coronary intervention
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy of atorvastatin on renal function in patients with contrast-induced nephropathy after percutaneous coronary intervention
Do you wish to request the book?
Efficacy of atorvastatin on renal function in patients with contrast-induced nephropathy after percutaneous coronary intervention
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy of atorvastatin on renal function in patients with contrast-induced nephropathy after percutaneous coronary intervention
2024
Overview
Background
At present, the clinical methods for preventing and treating contrast-induced nephropathy (CIN) are limited, and statins can play a better role during this process. So, we aimed to assess the atorvastatin on renal function in nephropathy patients after percutaneous coronary intervention (PCI).
Methods
In this work, 100 elderly patients with coronary heart disease (CHD) were selected into an experimental group (Exp group, 50 cases, 40 mg/d po atorvastatin) and a control group (Ctrl group, 50 cases, 10 mg/d po atorvastatin). The renal function indicators, blood routine indicators, and the incidence of adverse reactions (ARs) were compared between patients in Exp and Ctrl groups.
Results
After surgery, the levels of serum creatinine (SCr), blood urea nitrogen (BUN), cystatin C (CysC), high-sensitivity C-reactive protein (hs-CRP), and interleukin (IL6) in patients in the Exp group were much lower, and the levels of estimated glomerular filtration rate (eGFR) and superoxide dismutase (SOD) were higher (all
P
< 0.05). Meanwhile, the incidences of ARs during hospitalization between patients in the Exp and Ctrl groups were all 8%, showing no observable difference (
P
> 0.05). Compared with conventional doses of atorvastatin, high-dose atorvastatin can effectively prevent renal function damage in patients with CIN, decrease the inflammation and oxidative stress in patients, and will not increase the risk of ARs during hospitalization.
Conclusion
Taken together, high-dose atorvastatin can be applied in treating patients with CHD after PCI due to its excellent efficacy and high safety.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Anemia
/ Atorvastatin - adverse effects
/ Atorvastatin - therapeutic use
/ Blood
/ Contrast Media - adverse effects
/ Contrast-induced nephropathy
/ Diabetes
/ Estimated glomerular filtration rate
/ Female
/ Glomerular Filtration Rate - drug effects
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Kidney Diseases - chemically induced
/ Kidney Diseases - prevention & control
/ Male
/ Medicine
/ Patients
/ Percutaneous Coronary Intervention
/ Statins
/ Surgery
/ Urea
